A citation-based method for searching scientific literature

A Gaedigk, L Ndjountché, K Divakaran, L Dianne Bradford, I Zineh, T F Oberlander, D C Brousseau, D G McCarver, J A Johnson, S W Alander, K Wayne Riggs, J Steven Leeder. Clin Pharmacol Ther 2007
Times Cited: 105







List of co-cited articles
1246 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.
A Gaedigk, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder. Clin Pharmacol Ther 2008
517
49

CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Andrea Gaedigk, L Dianne Bradford, Sarah W Alander, J Steven Leeder. Drug Metab Dispos 2006
72
44

Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants.
Andrea Gaedigk, Lazara Karelia Montane Jaime, Joseph S Bertino, Anick Bérard, Victoria M Pratt, L Dianne Bradfordand, J Steven Leeder. Front Pharmacol 2010
50
54

CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.
Andrea Gaedigk, Uwe Fuhr, Charlene Johnson, L Anick Bérard, Dianne Bradford, J Steven Leeder. Pharmacogenomics 2010
51
50

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Ulrich M Zanger, Sebastian Raimundo, Michel Eichelbaum. Naunyn Schmiedebergs Arch Pharmacol 2004
587
25

CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR.
Andrea Gaedigk, Greyson P Twist, J Steven Leeder. Pharmacogenomics 2012
57
42


Complexities of CYP2D6 gene analysis and interpretation.
Andrea Gaedigk. Int Rev Psychiatry 2013
139
22

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Magnus Ingelman-Sundberg, Sarah C Sim, Alvin Gomez, Cristina Rodriguez-Antona. Pharmacol Ther 2007
772
21


Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
J Kirchheiner, K Nickchen, M Bauer, M-L Wong, J Licinio, I Roots, J Brockmöller. Mol Psychiatry 2004
497
18

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Andrea Gaedigk, L DiAnne Bradford, Kenda A Marcucci, J Steven Leeder. Clin Pharmacol Ther 2002
150
18

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.
Johanna Sistonen, Antti Sajantila, Oscar Lao, Jukka Corander, Guido Barbujani, Silvia Fuselli. Pharmacogenet Genomics 2007
268
18





Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam,[...]. Clin Pharmacol Ther 2014
405
16

The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.
Andrea Gaedigk, Magnus Ingelman-Sundberg, Neil A Miller, J Steven Leeder, Michelle Whirl-Carrillo, Teri E Klein. Clin Pharmacol Ther 2018
194
15

Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.
A Gaedigk, A Bhathena, L Ndjountché, R E Pearce, S M Abdel-Rahman, S W Alander, L DiAnne Bradford, P K Rogan, J Steven Leeder. Pharmacogenomics J 2005
65
21

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.
Gideon Koren, James Cairns, David Chitayat, Andrea Gaedigk, Steven J Leeder. Lancet 2006
392
14

Prediction of CYP2D6 phenotype from genotype across world populations.
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein, J Steven Leeder. Genet Med 2017
252
14

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.
M J Blake, A Gaedigk, R E Pearce, L R Bomgaars, M L Christensen, C Stowe, L P James, J T Wilson, G L Kearns, J S Leeder. Clin Pharmacol Ther 2007
116
13

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
J K Hicks, J J Swen, C F Thorn, K Sangkuhl, E D Kharasch, V L Ellingrod, T C Skaar, D J Müller, A Gaedigk, J C Stingl. Clin Pharmacol Ther 2013
287
13


Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, M Ingelman-Sundberg. J Pharmacol Exp Ther 1996
305
12

CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection.
Naoya Hosono, Mamoru Kato, Kazuma Kiyotani, Taisei Mushiroda, Sadaaki Takata, Hiroko Sato, Hanae Amitani, Yumiko Tsuchiya, Keiko Yamazaki, Tatsuhiko Tsunoda,[...]. Clin Chem 2009
62
19



Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
484
12

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
I Johansson, E Lundqvist, L Bertilsson, M L Dahl, F Sjöqvist, M Ingelman-Sundberg. Proc Natl Acad Sci U S A 1993
542
11

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
S Raimundo, J Fischer, M Eichelbaum, E U Griese, M Schwab, U M Zanger. Pharmacogenetics 2000
156
11

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Sebastian Raimundo, Claudia Toscano, Kathrin Klein, Joachim Fischer, Ernst-Ulrich Griese, Michel Eichelbaum, Matthias Schwab, Ulrich M Zanger. Clin Pharmacol Ther 2004
140
11


Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
E U Griese, U M Zanger, U Brudermanns, A Gaedigk, G Mikus, K Mörike, T Stüven, M Eichelbaum. Pharmacogenetics 1998
247
10

Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
A Wennerholm, I Johansson, M Hidestrand, L Bertilsson, L L Gustafsson, M Ingelman-Sundberg. Pharmacogenetics 2001
66
15

CYP2D6: novel genomic structures and alleles.
Whitney E Kramer, Denise L Walker, Dennis J O'Kane, David A Mrazek, Pamela K Fisher, Brian A Dukek, Jamie K Bruflat, John L Black. Pharmacogenet Genomics 2009
40
25

Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants.
Lazara Karelia Montané Jaime, Anthony Lalla, Werner Steimer, Andrea Gaedigk. Pharmacogenomics 2013
34
29

Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.
Wanqiong Qiao, Yao Yang, Robert Sebra, Geetu Mendiratta, Andrea Gaedigk, Robert J Desnick, Stuart A Scott. Hum Mutat 2016
53
18

CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing.
W-M Cai, D M Nikoloff, R-M Pan, J de Leon, P Fanti, M Fairchild, W H Koch, P J Wedlund. Pharmacogenomics J 2006
74
12

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
M Oscarson, M Hidestrand, I Johansson, M Ingelman-Sundberg. Mol Pharmacol 1997
120
9


Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
V M Steen, O A Andreassen, A K Daly, T Tefre, A L Børresen, J R Idle, A K Gulbrandsen. Pharmacogenetics 1995
241
9

Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
A Gaedigk, R R Gotschall, N S Forbes, S D Simon, G L Kearns, J S Leeder. Pharmacogenetics 1999
152
9

Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
A K Daly, K S Fairbrother, O A Andreassen, S J London, J R Idle, V M Steen. Pharmacogenetics 1996
46
19

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Hongwu Shen, Minxia M He, Houfu Liu, Steven A Wrighton, Li Wang, Bin Guo, Chuan Li. Drug Metab Dispos 2007
126
9

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
Leif Bertilsson, Marja-Liisa Dahl, Per Dalén, Ayman Al-Shurbaji. Br J Clin Pharmacol 2002
355
9


Polymorphic hydroxylation of Debrisoquine in man.
A Mahgoub, J R Idle, L G Dring, R Lancaster, R L Smith. Lancet 1977
9

CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Elke Schaeffeler, Matthias Schwab, Michel Eichelbaum, Ulrich M Zanger. Hum Mutat 2003
129
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.